ArticleScientific reports2021
Development of surface engineered antigenic exosomes as vaccines for respiratory syncytial virus.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- A review of recent advances in exosome-mediated drug delivery for regenerative therapy and immunomodulation.Biomedical engineering online · 2026Review
- Urinary Extracellular Vesicles for High-Precision Bladder Cancer Subtyping and Prognosis.Journal of extracellular biology · 2026Article
- Hijacking exosome biogenesis: viral glycoproteins as modular scaffolds for engineering functionalized extracellular vesicles.Nanoscale · 2026Article
- Targeted delivery of doxorubicin using RSV F-protein modified breast cancer-derived exosomes in breast cancer-bearing mice.BioImpacts : BI · 2026Article
- Extracellular vesicles as vaccine platforms: emerging opportunities for malaria.Frontiers in immunology · 2026Review
- Extracellular vesicles as new-age vaccine carriers: a focused account on viral diseases.Frontiers in immunology · 2026Review
- Multifunctional Engineering of Exosomes for Precision Therapeutics: Strategies for Targeted Delivery, Barrier Evasion, and Clinical Translation.Pharmaceutical research · 2025Review
- Urinary extracellular vesicles for high-precision bladder cancer subtyping and prognosis.medRxiv : the preprint server for health sciences · 2025Article
- The ExoGAN generative AI framework enables extracellular vesicle-based immunotherapy.Research square · 2025Article
- Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.Vaccines · 2025Review
- Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control.NPJ vaccines · 2025Review
- Extracellular vesicles and their mimetics: clinical application prospects in medical aesthetics.Burns & trauma · 2025Article
- Review
- SARS-CoV-2 antigen-carrying extracellular vesicles activate T cell responses in a human immunogenicity model.iScience · 2024Article
- Improvement in Yield of Extracellular Vesicles Derived from Edelweiss Callus Treated with LED Light and Enhancement of Skin Anti-Aging Indicators.Current issues in molecular biology · 2023Article
- IL-8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR-146a mediated mechanism.Molecular carcinogenesis · 2023Article
- Exosomal transmission of viruses, a two-edged biological sword.Cell communication and signaling : CCS · 2023Review
- Function and clinical application of exosome-how to improve tumor immunotherapy?Frontiers in cell and developmental biology · 2023Review
- Engineered exosomes for studies in tumor immunology.Immunological reviews · 2022Review
- Extracellular vesicle: A magic lamp to treat skin aging, refractory wound, and pigmented dermatosis?Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Respiratory syncytial virus (RSV) is one of the main pathogens associated with lower respiratory tract infections in infants and young children worldwide. Exosomes secreted by antigen presenting cells (APCs) can elicit immune responses by carrying major histocompatibility complex (MHC) class I molecules complexed with antigenic peptides and other co-stimulating factors. Therefore, we developed novel immunomagnetic nanographene particles to sequentially isolate, surface engineer, and release intact dendritic cell (DC) exosomes for use as a potential vaccine platform against RSV. The H-2D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.